Antiseptic pharmaceutical composition useful for the treatment of painful lesions in oral mucosa, ulcerative and inflammatory lesions of different origin and the treatment and/or prevention of oral mucositis and stomatitis.

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating iron overload disorders. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and reduced liver iron accumulation and serum iron parameters in both prophylactic and treatment mouse models.

The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of Mauritia flexuosa origin and a hibiscus acid, and wherein the second composition has a sun protection factor (SPF) of at least 15.

The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of Mauritia flexuosa origin and a hibiscus acid, and wherein the second composition has a sun protection factor (SPF) of at least 15.

Described herein is a method and corresponding composition of matter for inhibiting the growth of fungi and oomycetes. The method includes contacting fungi or oomycetes with a growth inhibitory effective amount of one or more compounds selected from p-hydroxycoumaryl aldehyde, coniferyl aldehyde, and sinapaldehyde, and salts and esters thereof.

Described herein is a method and corresponding composition of matter for inhibiting the growth of fungi and oomycetes. The method includes contacting fungi or oomycetes with a growth inhibitory effective amount of one or more compounds selected from p-hydroxycoumaryl aldehyde, coniferyl aldehyde, and sinapaldehyde, and salts and esters thereof.

Agonists for the TRPM-8 receptor, more particularly one or more substances selected from the group of, for example, linalool, geraniol, hydroxycitronellal, WS-3 (N-ethyl-p-menthane-3-carboxamide), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide), Frescolat MAG (1,4-dioxaspiro[4.5]decane-2-methanol), Frescolat ML (menthyl lactate), Coolact P (5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol) and Cooling Agent 10 (menthoxypropanediol), for use as medicaments to counter atopic dermatitis.

Agonists for the TRPM-8 receptor, more particularly one or more substances selected from the group of, for example, linalool, geraniol, hydroxycitronellal, WS-3 (N-ethyl-p-menthane-3-carboxamide), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide), Frescolat MAG (1,4-dioxaspiro[4.5]decane-2-methanol), Frescolat ML (menthyl lactate), Coolact P (5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol) and Cooling Agent 10 (menthoxypropanediol), for use as medicaments to counter atopic dermatitis.

Agonists for the TRPM-8 receptor, more particularly one or more substances selected from the group of, for example, linalool, geraniol, hydroxycitronellal, WS-3 (N-ethyl-p-menthane-3-carboxamide), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide), Frescolat MAG (1,4-dioxaspiro[4.5]decane-2-methanol), Frescolat ML (menthyl lactate), Coolact P (5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol) and Cooling Agent 10 (menthoxypropanediol), for use as medicaments to counter atopic dermatitis.

The invention is directed to a composition that safely removes a cured dental cement or resin from metal brackets, metal braces, and enamel surfaces of teeth. It contains eugenol, isoeugenol, methyl-eugenol or an isomer thereof. A method for removing orthodontic fixtures adhered with a dental cement or resin to the enamel surfaces of teeth from these surfaces by contacting the dental cement or resin with a composition containing eugenol.